B cell aplasia and hypogammaglobulinemia associated with levetiracetam

Levetiracetam (LEV) is a second-generation antiepileptic drug approved for the treatment of several types of epilepsy. We report a 45-year-old female who developed hypogammaglobulinemia and B cell aplasia during LEV treatment. The Naranjo probability score for an adverse drug reaction was 6. After L...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozdemir, Hulya, Sumer, Sua, Karabagli, Hakan, Akdemir, Gokhan, Caliskaner, A. Zafer, Artac, Hasibe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074184/
https://www.ncbi.nlm.nih.gov/pubmed/29313528
http://dx.doi.org/10.5144/0256-4947.2018.09.01.1430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074184/
https://www.ncbi.nlm.nih.gov/pubmed/29313528
http://dx.doi.org/10.5144/0256-4947.2018.09.01.1430

Ejemplares similares